Jacob Johnson
Stock Analyst at Stephens & Co.
(3.45)
# 882
Out of 4,784 analysts
77
Total ratings
44.07%
Success rate
6.21%
Average return
Main Sectors:
Stocks Rated by Jacob Johnson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| STE STERIS | Reiterates: Overweight | $240 | $223.00 | +7.62% | 7 | Feb 6, 2025 | |
| MASS 908 Devices | Reiterates: Overweight | $6 | $4.04 | +48.51% | 4 | Jan 15, 2025 | |
| LFCR Lifecore Biomedical | Reiterates: Equal-Weight | $6 | $6.85 | -12.41% | 4 | Jan 3, 2025 | |
| AZTA Azenta | Reiterates: Overweight | $60 | $34.61 | +73.36% | 6 | Jan 2, 2025 | |
| DHR Danaher | Reiterates: Overweight | $315 | $205.85 | +53.02% | 2 | Oct 23, 2024 | |
| TMO Thermo Fisher Scientific | Initiates: Overweight | $680 | $500.16 | +35.96% | 1 | Oct 1, 2024 | |
| RGEN Repligen | Reiterates: Overweight | $170 | $133.41 | +27.43% | 4 | Jul 30, 2024 | |
| TKNO Alpha Teknova | Reiterates: Overweight | $5 | $5.21 | -4.03% | 5 | Jul 10, 2024 | |
| MXCT MaxCyte | Reiterates: Overweight | $11 | $2.73 | +302.93% | 5 | Apr 23, 2024 | |
| STVN Stevanato Group | Reiterates: Overweight | $38 | $20.29 | +87.28% | 2 | Mar 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $17 | $6.09 | +179.15% | 3 | Mar 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $2.5 | $1.42 | +76.06% | 3 | Mar 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $92 → $87 | $58.73 | +48.14% | 10 | Feb 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $420 → $390 | $222.20 | +75.52% | 8 | Oct 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $16 → $18 | $9.62 | +87.11% | 5 | Aug 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $6 | $2.81 | +113.52% | 2 | Jul 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $27 → $29 | $25.96 | +11.71% | 3 | Jul 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $153 → $130 | $107.62 | +20.80% | 2 | May 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $377 | $155.55 | +142.37% | 1 | Apr 7, 2022 |
STERIS
Feb 6, 2025
Reiterates: Overweight
Price Target: $240
Current: $223.00
Upside: +7.62%
908 Devices
Jan 15, 2025
Reiterates: Overweight
Price Target: $6
Current: $4.04
Upside: +48.51%
Lifecore Biomedical
Jan 3, 2025
Reiterates: Equal-Weight
Price Target: $6
Current: $6.85
Upside: -12.41%
Azenta
Jan 2, 2025
Reiterates: Overweight
Price Target: $60
Current: $34.61
Upside: +73.36%
Danaher
Oct 23, 2024
Reiterates: Overweight
Price Target: $315
Current: $205.85
Upside: +53.02%
Thermo Fisher Scientific
Oct 1, 2024
Initiates: Overweight
Price Target: $680
Current: $500.16
Upside: +35.96%
Repligen
Jul 30, 2024
Reiterates: Overweight
Price Target: $170
Current: $133.41
Upside: +27.43%
Alpha Teknova
Jul 10, 2024
Reiterates: Overweight
Price Target: $5
Current: $5.21
Upside: -4.03%
MaxCyte
Apr 23, 2024
Reiterates: Overweight
Price Target: $11
Current: $2.73
Upside: +302.93%
Stevanato Group
Mar 25, 2024
Reiterates: Overweight
Price Target: $38
Current: $20.29
Upside: +87.28%
Mar 13, 2024
Reiterates: Equal-Weight
Price Target: $17
Current: $6.09
Upside: +179.15%
Mar 7, 2024
Reiterates: Equal-Weight
Price Target: $2.5
Current: $1.42
Upside: +76.06%
Feb 2, 2024
Maintains: Overweight
Price Target: $92 → $87
Current: $58.73
Upside: +48.14%
Oct 27, 2023
Maintains: Overweight
Price Target: $420 → $390
Current: $222.20
Upside: +75.52%
Aug 21, 2023
Upgrades: Overweight
Price Target: $16 → $18
Current: $9.62
Upside: +87.11%
Jul 21, 2023
Reiterates: Overweight
Price Target: $6
Current: $2.81
Upside: +113.52%
Jul 17, 2023
Maintains: Overweight
Price Target: $27 → $29
Current: $25.96
Upside: +11.71%
May 16, 2022
Maintains: Overweight
Price Target: $153 → $130
Current: $107.62
Upside: +20.80%
Apr 7, 2022
Initiates: Overweight
Price Target: $377
Current: $155.55
Upside: +142.37%